Table 1.

Observed events related to efficacy endpoints

Treatment group		Recurrent VTE		Recurrent DVT + nonfatal PE		Recurrent DVT + nonfatal PE + all‐cause mortality
	Total no. of patients	No. of first events	% of events	No. of first events	% of events	No. of first events	% of events
Warfarin	4,122	80	1.94	71	1.72	100	2.43
Edoxaban
60 mg full dose	3,385	53	1.57	46	1.36	66	1.95
30 mg reduced dose	733	13	1.77	9	1.23	18	2.46

DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.